

FORM 9

NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES

(or securities convertible or exchangeable into listed securities¹)

Name of Listed Issuer:

Symbol(s):

Aretto Wellness Inc. (the "Issuer" or the "Company").

ARTO

Date: January 9, 2023

Is this an updating or amending Notice: ☐Yes ☒No

If yes provide date(s) of prior Notices: _____

Issued and Outstanding Securities of Issuer Prior to Issuance: 5,532,862

Pricing

Date of news release announcing proposed issuance: December 30, 2022 or

Date of confidential request for price protection: _____

Closing Market Price on Day Preceding the news release: \$0.06 or

Day preceding request for price protection: _____

Closing

Number of securities to be issued: 5,337,501

Issued and outstanding securities following issuance: 10,870,363

Instructions:

1. For private placements (including debt settlement), complete tables 1A and 1B in Part 1 of this form.
2. Complete Table 1A – Summary for all purchasers, excluding those identified in Item 8.
3. Complete Table 1B – Related Persons only for Related Persons
4. If shares are being issued in connection with an acquisition (either as consideration or to raise funds for a cash acquisition) please proceed to Part 2 of this form.
5. An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10 – Notice of Proposed Transaction
6. Post the completed Form 9 to the CSE website in accordance with *Policy 6 – Distributions*. In addition, the completed form must be delivered to listings@thecse.com with an appendix that includes the information in Table 1B for ALL placees.

Part 1. Debt Conversions

Table 1A – Summary

Each jurisdiction in which purchasers reside	Number of Purchasers	Price per Security	Total dollar value (CDN\$)
British Columbia	8	\$0.075	\$330,312.50
Alberta	2	\$0.075	\$70,000.00
Total number of purchasers:	1		
Total dollar value of distribution in all jurisdictions:			\$400,312.50

Table 1B – Related Persons

Full Name & Municipality of Residence of Placee	Number of Securities Purchased or to be Purchased	Purchase price per Security (CDN\$)	Conversion Price (if Applicable) (CDN\$)	Prospectus Exemption	Total Securities Previously Owned, Controlled or Directed	Payment Date ⁽¹⁾	Describe relationship to Issuer (2)
1329058 B.C. Ltd. (Robert Payment)	738,500 common shares	0.075	-	NI 45-106 s. 2.14	738,500	-	Officer
RME Enterprises Ltd. (Warren Spence)	336,000 common shares	0.075	-	NI 45-106 s. 2.14	336,000	-	Director

¹An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10.

1. Total amount of funds to be raised: \$nil.
2. Provide full details of the use of the proceeds. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material: 5,337,501 common shares (the “Shares for Debt”) are being issued to creditors (the “Creditors”) pursuant to debt conversion agreements respectively between the Issuer and

each of the Creditors. The parties have agreed that the Issuer will issue the Shares for Debt to the Creditors in exchange for the extinguishment and cancellation of an aggregate of \$400,312.50 in debt owed by the Issuer to the Creditors.

3. Provide particulars of any proceeds which are to be paid to Related Persons of the Issuer: As set out in Table 1B hereof, two insiders of the Company will receive 1,074,500 Shares for Debt, in forgiveness of outstanding debts owed to them.
4. If securities are issued in forgiveness of indebtedness, provide details of the debt agreement(s) or and the agreement to exchange the debt for securities.
5. Description of securities to be issued:
 - (a) Class: Common shares
 - (b) Number: 5,337,501
 - (c) Price per security: \$0.075
 - (d) Voting rights: One vote per common share held
6. Provide the following information if warrants, (options) or other convertible securities are to be issued: N/A
 - (a) Number _____ .
 - (b) Number of securities eligible to be purchased on exercise of warrants (or options) _____ .
_____ .
 - (c) Exercise price _____ .
 - (d) Expiry date _____ .
7. Provide the following information if debt securities are to be issued: N/A
 - (a) Aggregate principal amount _____ .
 - (b) Maturity date _____ .
 - (c) Interest rate _____ .
 - (d) Conversion terms _____ .
 - (e) Default provisions _____ .

8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the placement (including warrants, options, etc.): N/A
- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the placement (name, and if a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): ____ .
- (b) Cash _____ .
- (c) Securities _____ .
- (d) Other _____ .
- (e) Expiry date of any options, warrants etc. _____ .
- (f) Exercise price of any options, warrants etc. _____ .
9. State whether the sales agent, broker, dealer or other person receiving compensation in connection with the placement is Related Person or has any other relationship with the Issuer and provide details of the relationship. N/A
10. Describe any unusual particulars of the transaction (i.e. tax "flow through" shares, etc.) N/A
11. State whether the private placement will result in a change of control. No
12. Where there is a change in the control of the Issuer resulting from the issuance of the private placement shares, indicate the names of the new controlling shareholders. N/A
13. Each purchaser has been advised of the applicable securities legislation restricted or seasoning period. All certificates for securities issued which are subject to a hold period bear the appropriate legend restricting their transfer until the expiry of the applicable hold period required by National Instrument 45-102 Resale of Securities. Yes

Part 2. Acquisition – N/A

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.
2. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed.
3. the Issuer has obtained the express written consent of each applicable individual to:
 - (a) the disclosure of their information to the Exchange pursuant to this Form or otherwise pursuant to this filing; and
 - (b) the collection, use and disclosure of their information by the Exchange in the manner and for the purposes described in Appendix A or as otherwise identified by the Exchange, from time to time
4. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CSE Policy 1).
5. All of the information in this Form 9 Notice of Issuance of Securities is true.

Dated January 9, 2023.

Robert Payment
Name of Director or Senior
Officer

/s/ Robert Payment
Signature

CFO
Official Capacity